Acinar Adenocarcinoma of the Prostate (Conventional): The Diagnostic Baseline

What it is, and where it sits in the classification

Acinar adenocarcinoma is the prostate cancer most pathologists picture when they hear the phrase. It's the dominant malignancy of the gland and the default diagnosis against which every other subtype is measured. In the 5th edition of the WHO classification of urinary and male genital tumours, conventional acinar adenocarcinoma is a recognized entity that serves as the reference point for the family of acinar variants and the separately categorized ductal, intraductal, and other patterns [1].

Its architecture is deceptively simple: infiltrative small glands that have lost their basal cell layer. That single structural fact—glands growing where they shouldn't, without the scaffolding a benign gland retains—anchors the entire diagnosis. Everything else refines it.

How a pathologist recognizes it: morphology first

The diagnosis begins under the microscope, and it stays there for as long as the morphology will carry it. Three features converge. First, infiltrative growth—small glands crowding between benign structures rather than respecting lobular boundaries. Second, nucleomegaly with prominent nucleoli, the cytologic signal that something has gone wrong at the level of the individual cell. Third, and most decisive, the absence of a basal cell layer [1].

Benign prostatic glands are two-layered. They keep a continuous or patchy basal cell population beneath the luminal cells. Malignant acinar glands don't. That loss is the structural crux of the diagnosis, and on a well-sampled focus with convincing architecture and nucleolar prominence, an experienced eye needs nothing more.

Small foci are the problem. A handful of atypical glands at the edge of a needle core won't always declare themselves on morphology alone. That's where immunohistochemistry earns its place.

When morphology isn't enough: the IHC triad

The confirmatory workup rests on a complementary triad, and the logic of it is worth spelling out because each marker answers a different question.

Basal cell markers—p63 and high-molecular-weight cytokeratin—should be absent in carcinoma. Their loss confirms the basal layer is genuinely gone rather than merely inconspicuous. AMACR (P504S) is typically positive, marking the enzymatic shift that characterizes malignant acinar epithelium. NKX3.1 is positive, confirming prostatic lineage—useful when the question is whether a poorly differentiated tumour arose in the prostate at all [1].

Put together: basal markers negative (it's not benign), AMACR positive (it behaves like carcinoma), NKX3.1 positive (it's prostatic). In practice, the full triad rarely needs to be deployed when the morphology is already convincing. It's the ambiguous small focus—a few glands, borderline nuclei—where the panel does its real work and where a clean negative basal stain settles the matter.

Molecular findings

Molecular characterization sits downstream of morphology and IHC in the diagnostic order, and for conventional acinar adenocarcinoma it's largely descriptive rather than diagnostic. Roughly half of cases harbour a TMPRSS2::ERG fusion, which places an androgen-regulated promoter upstream of an ETS transcription factor—an early and recurrent event in prostatic carcinogenesis [1]. PTEN loss is another recurrent alteration, associated with more aggressive biology. A further subset is driven by SPOP or FOXA1 mutations, defining molecularly distinct groups within what looks, on the slide, like a single entity [1].

None of these is required to make the diagnosis. They matter because they remind us that a morphologically uniform tumour can be genetically heterogeneous, and that the biology beneath the glass isn't as monolithic as the H&E suggests.

Grading: the axis that actually drives management

Here's the point that surprises trainees: the subtype label matters less than the grade. For conventional acinar adenocarcinoma, risk stratification runs through the Gleason system, which architectural patterns are scored and then translated into ISUP Grade Groups 1 through 5 [2].

The Grade Group framework was refined at the 2014 ISUP consensus conference to sharpen prognostic separation and to correct a long-standing communication problem—patients and clinicians reading a Gleason 6 out of a possible 10 and assuming an intermediate cancer, when it's the lowest grade assigned [2]. Grade Group 1 corresponds to Gleason 6; Grade Group 5 to Gleason 9–10. That relabelling changed conversations, not just data tables.

Grading, not subtyping, carries the prognostic weight for conventional acinar tumours. Two patients with the same diagnosis and different Grade Groups occupy very different clinical positions.

Why the distinction matters clinically

The therapeutic relevance of the molecular findings is at the level of drug-class eligibility rather than any individual recommendation. Alterations such as PTEN loss and the broader molecular subsets can inform which classes of therapy a tumour may be eligible for consideration under, but that determination belongs to the treating team and the broader clinical picture—never to the slide alone.

What the pathology report delivers is a defensible malignant diagnosis and an accurate grade. Both are load-bearing. A misassigned Grade Group doesn't just misdescribe a tumour—it can shift a patient between surveillance and intervention, which is why the reproducibility work behind the Grade Groups was worth doing [2].

The genuine difficulty in daily practice isn't recognizing a florid high-grade cancer; it's the minimal focus. A few atypical glands, equivocal nuclei, a basal stain that's patchy rather than clean-negative—these are the cases where the triad, the architecture, and the pathologist's threshold for calling malignancy all have to align. Get that focus right, grade it accurately, and the rest of the care pathway has a foundation to stand on. Get it wrong, and every downstream decision inherits the error.

References

1. WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours, 5th ed. Lyon: IARC; 2022. ISBN 978-92-832-4512-4.
2. Epstein JI, et al. The 2014 ISUP Consensus Conference on Gleason Grading / Grade Groups. Am J Surg Pathol. 2016. doi:10.1097/PAS.0000000000000530.